Eli Lilly's shares have fallen 2.7% since its second-quarter earnings report, underperforming the S&P 500, but the company's strong results and raised guidance suggest a possible rebound. In the quarter, Lilly reported adjusted EPS of $8.38, beating the Zacks Consensus Estimate of $6.01, and revenues of $22.97 billion, up 48% year over year, surpassing the consensus of $20.26 billion. Sales of Mounjaro and Zepbound, key growth drivers, reached $9.94 billion and $4.93 billion, respectively, both beating estimates. The company raised its full-year 2026 revenue guidance to $85-$87 billion from $82-$85 billion, though it narrowed adjusted EPS guidance to $35.50-$36.50 per share due to acquired IPR&D charges. Analysts have revised estimates upward since the report, and Lilly holds a Zacks Rank #3 (Hold) with a VGM Score of B.
Eli Lilly and CompanyQ2 earnings beat and raised revenue guidance indicate strong performance
AbbVie Inc